| pubmed-article:2145212 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2145212 | lifeskim:mentions | umls-concept:C0062527 | lld:lifeskim |
| pubmed-article:2145212 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:2145212 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
| pubmed-article:2145212 | lifeskim:mentions | umls-concept:C0021740 | lld:lifeskim |
| pubmed-article:2145212 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:2145212 | pubmed:issue | 4 Pt 1 | lld:pubmed |
| pubmed-article:2145212 | pubmed:dateCreated | 1990-11-1 | lld:pubmed |
| pubmed-article:2145212 | pubmed:abstractText | Patients undergoing long-term hemodialysis are at high risk of acquiring hepatitis B yet tend to have poor rates of response to hepatitis B vaccine. The effect of recombinant human gamma-interferon (2 million units/m2) on the response to a recombinant hepatitis B vaccine was evaluated in a prospective, randomized controlled trial in 81 hemodialysis patients. A similar proportion of both groups of vaccinees ultimately developed antibody to HBsAg including 81% of the 41 recipients of vaccine alone (group I) and 89% of the 40 recipients of vaccine with gamma-interferon (group II). However, the antibody to HBsAg response occurred earlier in recipients of vaccine with gamma-interferon, so that at 4 mo 63% of group I and 88% of group II had antibody to HBsAg (p less than 0.025). Furthermore, titers of antibody to HBsAg tended to be higher in the vaccinees given interferon; the final geometric mean titers were 232 IU/L in group I and 330 IU/L in group II (p = not significant). Retrospective testing for antibody to hepatitis C virus revealed that 21 (26%) hemodialysis patients were seropositive at entry into this trial, but the presence of antibody to hepatitis C virus did not appear to affect the response rate to the hepatitis B vaccine. These results suggest that the effects of gamma-interferon as an adjuvant in increasing the response rate to hepatitis B vaccination deserve further evaluation perhaps most appropriately in persons who have not responded to an initial course of vaccine. | lld:pubmed |
| pubmed-article:2145212 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2145212 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2145212 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2145212 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2145212 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2145212 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2145212 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2145212 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2145212 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2145212 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2145212 | pubmed:issn | 0270-9139 | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:CasadoSS | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:MoraAA | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:GómezMM | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:CastilloII | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:QuirogaJ AJA | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:PorresJ CJC | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:IngladaLL | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:Sánchez-Sicil... | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:SáezFF | lld:pubmed |
| pubmed-article:2145212 | pubmed:author | pubmed-author:Gracia... | lld:pubmed |
| pubmed-article:2145212 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2145212 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:2145212 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2145212 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2145212 | pubmed:pagination | 661-3 | lld:pubmed |
| pubmed-article:2145212 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:meshHeading | pubmed-meshheading:2145212-... | lld:pubmed |
| pubmed-article:2145212 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2145212 | pubmed:articleTitle | Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. | lld:pubmed |
| pubmed-article:2145212 | pubmed:affiliation | Department of Gastroenterology, Fundación Jiménez Díaz, Madrid, Spain. | lld:pubmed |
| pubmed-article:2145212 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2145212 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2145212 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
